Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clofibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | FBP1 | P09467 | 5/20 | 0.57 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofibrate SCHEMBL2356 | 1.00 | PPARA (1.00) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL29262880 | 0.98 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL5605019 | 0.98 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL3345 | 0.98 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11184809 | 0.98 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11187010 | 0.98 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11180679 | 0.98 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11175123 | 0.97 | PPARA (0.94) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL28086141 | 0.97 | PPARA (0.94) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL21992458 | 0.95 | PPARA (0.91) | PPARACYP1A2CYP3A4ABCB11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| WO-2009033078-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING CHOLESTEROL LEVELS | TAWAKOL RAIF (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1817427-A2 | METHOD FOR DETERMINING GENOTOXICITY | F. Hoffmann-Roche AG (CH) | 2007-08-15 | — | — | EP | disclosed |
| EP-1684704-A2 | COMPOSITIONS AND METHODS FOR INCREASING HDL AND HDL-2B LEVELS | Tawakol, Raif M. (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2006056340-A2 | METHOD FOR DETERMINING GENOTOXICITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005041878-A2 | COMPOSITIONS AND METHODS FOR INCREASING HDL AND HDL-2B LEVELS | TAWAKOL RAIF M D (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-4871752-A | Use of aryloxycarboxylic acid derivatives against dermatological diseases | ILG LASZLO (DE) | 1989-10-03 | — | — | US | disclosed |